Personalis, Inc.
PSNL
Rank in Stocks
#6451
Personalis, Inc. operates globally as a specialized cancer genomics firm. The... Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Share Price
$15.95
Last synced: 2026-11-09
Market Cap
$1.73B
Change (1 day)
1.01%
Change (1 year)
88.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Personalis, Inc. (PSNL)
Category
Healthcare
Operating Margin for Personalis, Inc. (PSNL)
Operating Margin as of November 2026 TTM: -164.07%
According to Personalis, Inc.'s latest financial reports, its current operating margin (TTM) is -164.07%. At the end of 2025 the company had an operating margin of -126.43%.
Operating Margin history for Personalis, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -164.07% | 29.77% |
| 2025 | -126.43% | 56.71% |
| 2024 | -80.68% | -46.07% |
| 2023 | -149.61% | -15.76% |
| 2022 | -177.61% | 132.35% |
| 2021 | -76.44% | 42.64% |
| 2020 | -53.59% | 55.88% |
| 2019 | -34.38% | -5.68% |
| 2018 | -36.45% | -84.55% |
| 2017 | -235.95% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -100.11% |
US
|
|
| 20.38% | -100.12% |
US
|
|
| 43.02% | -100.26% |
CN
|
|
| 32.03% | -100.20% |
US
|
|
| 22.23% | -100.14% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Personalis, Inc.'s operating margin
What is Personalis, Inc.'s operating margin?
Personalis, Inc.'s operating margin is -164.07%, as of Nov 2026.
What was Personalis, Inc.'s operating margin in 2025?
In 2025, Personalis, Inc.'s operating margin was -126.43%, compared with -80.68% in 2024.
How has Personalis, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Personalis, Inc.'s operating margin was highest in 2020 (-53.59%) and lowest in 2022 (-177.61%).
How does Personalis, Inc.'s operating margin compare with similar companies?
Personalis, Inc.'s operating margin (-164.07%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.